Status:
COMPLETED
Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Psoriasis
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The investigators hypothesize that the inhibition of endogenous reverse transcriptase would: (1) reduce excess cytosolic DNA, stress initiating the inflammatory loop at the origin of psoriatic lesions...
Eligibility Criteria
Inclusion
- Patient suffering from plaque psoriasis for more than a year with at least one active skin lesion\> 4 cm2 in the photo-protected area.
- Patient using effective contraception (IUD, adapted pill, condom, etc.)
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
Exclusion
- Patient with another form or stage of psoriasis
- Patient on anti-cytokine treatment during the 6 months (180 days) before inclusion
- Patient under systemic treatment based on (1) corticosteroids, (2) antibiotics, (3) methotrexate, ciclosporin, soriatane, hydroxyurea, apremilast or (4) PUVA, (5) UVB, (6) vitamin D3 during the 4 weeks (28 days) before inclusion
- Patient on topical corticosteroid or retinoid treatment during the 2 weeks (15 days) before inclusion
- Patient with renal insufficiency; taking nephrotoxic agents (aminoglycosides, multiple or high doses of NSAIDs, etc.); creatinine clearance less than 50 ml / min; serum phosphorus below 1.0 mg / dl (0.32 mmol / l).
- Patient with active viral infection (HBV, HCV and HIV), or uncontrolled acute infection.
- Patient with hypersensitivity to one of the active substances or to any of the excipients (non-medicinal ingredients).
- Patient with uncontrolled coagulation disorder, history of keloid scars
- Patient with an allergy to local anesthetics; any condition likely to interfere at the time of the pre-inclusion visit, with the evaluation of the main objective such as eczema, psychiatric disorders
- Patient with uncontrolled systemic parameters The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
Key Trial Info
Start Date :
February 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 20 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04274595
Start Date
February 13 2020
End Date
June 20 2022
Last Update
December 10 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Montpellier
Montpellier, France, 34295
2
CHU de Nimes
Nîmes, France, 30029